<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204369">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000608</url>
  </required_header>
  <id_info>
    <org_study_id>111</org_study_id>
    <nct_id>NCT00000608</nct_id>
  </id_info>
  <brief_title>Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effects of three levels of dietary sodium and two patterns of diet (a control
      diet and an intervention diet high in fruits, vegetables, and low fat dairy products and low
      in fat) on blood pressure in individuals with higher than optimal blood pressure or with
      Stage 1 hypertension.. DASH - Sodium built on and extended the results of the
      NHLBI-initiated Dietary Approaches to Stop Hypertension (DASH) study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      High blood pressure, defined as systolic blood pressure greater than or equal to 140 mm Hg
      or diastolic blood pressure greater than or equal to 90 mm Hg, or taking antihypertensive
      medication, affects 24 percent of the United States adult population or about 50 million
      people. Because the risk of cardiovascular disease and stroke increases with increasing
      blood pressure throughout the entire range of blood pressure levels, people with blood
      pressure above the optimal level of 120/80 are at increased risk of disease. Approximately
      48 percent of the adult population have blood pressure either normal but above optimal
      levels or have Stage 1 hypertension, a prevalence which increases with age. To combat this
      highly prevalent condition, primary prevention through lifestyle modification represents a
      highly promising strategy for public health.

      DASH - Sodium extended research from DASH trial to address several issues of relevance to
      clinical practice and public health and capitalized on the success of DASH by following the
      multicenter outpatient feeding study model. The model permitted a true test of efficacy
      because of high adherence and follow-up rates. In addition, the population studied across
      four geographic areas, encompassing individuals with diastolic blood pressure between 80-95
      mm Hg and systolic blood pressure &lt;160 mm Hg, was broadly representative, thus making the
      results generalizable to a large portion of the United States population.

      DESIGN NARRATIVE:

      The effects on blood pressure of three levels of sodium intake and two dietary patterns were
      compared. The combined impact of sodium reduction with dietary intervention was evaluated as
      a potential non-pharmacologic treatment alternative to drug therapy for stage one
      hypertension or for maintaining normal blood pressure levels. The two dietary patterns were
      a control diet that represented the typical American diet and an intervention diet (DASH
      diet) that was high in fruits, vegetables, included whole grains, poultry, fish, and nuts,
      and reduced in fats, red meat, sweets, and sugar-containing beverages and dairy products.
      The three levels of sodium were higher (current United States intake), intermediate (current
      recommended levels), and lower (potentially optimal levels). Participants were assigned to
      one of the two dietary patterns using a parallel group design and were fed at each sodium
      level using a randomized cross-over design.

      Three eligibility pre-screening visits were followed by a two-week run-in feeding period and
      then a four-week intervention period at each of three sodium levels. During the run-in for
      the intervention feeding periods, all food was provided to participants. They were required
      to attend the clinic for at least one meal per day, five days per week, and to take home
      food to eat for other meals. Each of the four clinics recruited 100 participants. Blood
      pressure was measured once a week during the first of three weeks and five times during the
      last week. During the final feeding period, fasting blood was collected and 24-hour urine
      collections were analyzed for magnesium, potassium. calcium, sodium, and creatinine.

      DASH - Sodium determined, separately by race, gender, and hypertension status: 1) the
      effects on blood pressure of three levels of dietary sodium within the context of both a
      control diet and the DASH diet; 2) the effect on blood pressure of the DASH diet, relative
      to the control diet, at each of the three levels of sodium intake. The study also assessed
      whether the effect on blood pressure of going from higher to lower sodium diets differs for
      participants in the control and DASH diets. Lastly, the study determined whether the blood
      pressure effect associated with reducing sodium from the higher to the intermediate level
      differs from the blood pressure effect associated with reducing sodium from the intermediate
      to the lower level, that is, testing whether the blood pressure effects of sodium are linear
      across sodium levels for each diet.

      Recruitment and screening began in August 1997. The first cohort began the experimental
      diets in January 1998 and the last cohort completed the diets in November 1999. A total of
      412 participants were enrolled into the study. Results were presented at the annual meeting
      of American Society of Hypertension in May 2000.

      The study was renewed under R01HL57114 to to analyze the data of the trial The hypothesis to
      be tested is that genetic makeup modulates the BP effects of DASH diet and reduced sodium
      intake through one or more of the following mechanisms: 1) effects on vascular tone; 2)
      effects on mineralocorticoid regulation of sodium homeostasis; and 3) effects on
      non-classical regulation of sodium homeostasis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1997</start_date>
  <completion_date type="Actual">July 2002</completion_date>
  <primary_completion_date type="Actual">July 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Parallel Assignment, Primary Purpose: Prevention</study_design>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Hypertension</condition>
  <condition>Vascular Diseases</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>diet, fat-restricted</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>diet, sodium-restricted</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy adult men and women, ages 22 and older, who had a diastolic blood pressure of 80
        to 95 mm Hg and a systolic blood pressure less than 160 mm Hg.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Vollmer</last_name>
    <affiliation>Kaiser Foundation Research Institute</affiliation>
  </overall_official>
  <link>
    <url>http://www.brighamandwomens.org/patient/patient_dept_frame.asp?id=8</url>
  </link>
  <reference>
    <citation>Svetkey LP, Sacks FM, Obarzanek E, Vollmer WM, Appel LJ, Lin PH, Karanja NM, Harsha DW, Bray GA, Aickin M, Proschan MA, Windhauser MM, Swain JF, McCarron PB, Rhodes DG, Laws RL. The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group. J Am Diet Assoc. 1999 Aug;99(8 Suppl):S96-104.</citation>
    <PMID>10450301</PMID>
  </reference>
  <reference>
    <citation>Greenland P. Beating high blood pressure with low-sodium DASH. N Engl J Med. 2001 Jan 4;344(1):53-5.</citation>
    <PMID>11136961</PMID>
  </reference>
  <reference>
    <citation>Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10.</citation>
    <PMID>11136953</PMID>
  </reference>
  <reference>
    <citation>Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, Conlin PR, Svetkey LP, Erlinger TP, Moore TJ, Karanja N; DASH-Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001 Dec 18;135(12):1019-28.</citation>
    <PMID>11747380</PMID>
  </reference>
  <reference>
    <citation>Phillips KM, Simpkins AH, Amanna KR, Wolf W, Stewart KK, Clark S, Kim KP, Beecher GR, Holden J. Long-term stability of nutrients in a frozen mixed food control material. Fresenius J Anal Chem. 2001 Jun;370(2-3):297-302.</citation>
    <PMID>11451255</PMID>
  </reference>
  <reference>
    <citation>Conlin PR, Erlinger TP, Bohannon A, Miller ER 3rd, Appel LJ, Svetkey LP, Moore TJ. The DASH diet enhances the blood pressure response to losartan in hypertensive patients. Am J Hypertens. 2003 May;16(5 Pt 1):337-42.</citation>
    <PMID>12745193</PMID>
  </reference>
  <reference>
    <citation>Lin PH, Aickin M, Champagne C, Craddick S, Sacks FM, McCarron P, Most-Windhauser MM, Rukenbrod F, Haworth L; Dash-Sodium Collaborative Research Group. Food group sources of nutrients in the dietary patterns of the DASH-Sodium trial. J Am Diet Assoc. 2003 Apr;103(4):488-96.</citation>
    <PMID>12669013</PMID>
  </reference>
  <reference>
    <citation>Erlinger TP, Miller ER 3rd, Charleston J, Appel LJ. Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. Circulation. 2003 Jul 15;108(2):150-4. Epub 2003 Jul 7.</citation>
    <PMID>12847067</PMID>
  </reference>
  <reference>
    <citation>Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G; DASH-Sodium Trial Collaborative Research Group. Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship. Hypertension. 2003 Jul;42(1):8-13. Epub 2003 May 19.</citation>
    <PMID>12756219</PMID>
  </reference>
  <reference>
    <citation>JÃ¼rgens G, Graudal N; Dietary Approaches to Stop Hypertension. Subgroup results in the DASH-sodium trial. Ann Intern Med. 2002 Nov 5;137(9):772-3; author reply 772-3.</citation>
    <PMID>12416957</PMID>
  </reference>
  <reference>
    <citation>Harsha DW, Sacks FM, Obarzanek E, Svetkey LP, Lin PH, Bray GA, Aickin M, Conlin PR, Miller ER 3rd, Appel LJ. Effect of dietary sodium intake on blood lipids: results from the DASH-sodium trial. Hypertension. 2004 Feb;43(2):393-8. Epub 2004 Jan 5.</citation>
    <PMID>14707154</PMID>
  </reference>
  <reference>
    <citation>Most MM, Craddick S, Crawford S, Redican S, Rhodes D, Rukenbrod F, Laws R; Dash-Sodium Collaborative Research Group. Dietary quality assurance processes of the DASH-Sodium controlled diet study. J Am Diet Assoc. 2003 Oct;103(10):1339-46.</citation>
    <PMID>14520254</PMID>
  </reference>
  <reference>
    <citation>Obarzanek E, Proschan MA, Vollmer WM, Moore TJ, Sacks FM, Appel LJ, Svetkey LP, Most-Windhauser MM, Cutler JA. Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. Hypertension. 2003 Oct;42(4):459-67. Epub 2003 Sep 2.</citation>
    <PMID>12953018</PMID>
  </reference>
  <reference>
    <citation>Bray GA, Vollmer WM, Sacks FM, Obarzanek E, Svetkey LP, Appel LJ; DASH Collaborative Research Group. A further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: results of the DASH-Sodium Trial. Am J Cardiol. 2004 Jul 15;94(2):222-7. Erratum in: Am J Cardiol. 2010 Feb 15;105(4):579.</citation>
    <PMID>15246908</PMID>
  </reference>
  <reference>
    <citation>Svetkey LP, Simons-Morton DG, Proschan MA, Sacks FM, Conlin PR, Harsha D, Moore TJ. Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control. J Clin Hypertens (Greenwich). 2004 Jul;6(7):373-81.</citation>
    <PMID>15249792</PMID>
  </reference>
  <reference>
    <citation>Ard JD, Coffman CJ, Lin PH, Svetkey LP. One-year follow-up study of blood pressure and dietary patterns in dietary approaches to stop hypertension (DASH)-sodium participants. Am J Hypertens. 2004 Dec;17(12 Pt 1):1156-62.</citation>
    <PMID>15607623</PMID>
  </reference>
  <reference>
    <citation>Kennedy BM, Conlin PR, Ernst D, Reams P, Charleston JB, Appel LJ. Successfully recruiting a multicultural population: the DASH-Sodium experience. Ethn Dis. 2005 Winter;15(1):123-9.</citation>
    <PMID>15720059</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <lastchanged_date>January 15, 2008</lastchanged_date>
  <firstreceived_date>October 27, 1999</firstreceived_date>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
